3/26
08:42 am
vani
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/26
08:30 am
vani
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
3/6
08:11 am
vani
Vivani Medical Appoints Daniel Bradbury to its Board of Directors [Yahoo! Finance]
Low
Report
Vivani Medical Appoints Daniel Bradbury to its Board of Directors [Yahoo! Finance]
3/6
08:00 am
vani
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
Low
Report
Vivani Medical Appoints Daniel Bradbury to its Board of Directors
3/1
08:06 am
vani
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants [Yahoo! Finance]
Medium
Report
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants [Yahoo! Finance]
3/1
07:49 am
vani
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
Medium
Report
Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants
3/1
06:02 am
vani
Individual investors invested in Vivani Medical, Inc. (NASDAQ:VANI) up 287% last week, insiders too were rewarded [Yahoo! Finance]
High
Report
Individual investors invested in Vivani Medical, Inc. (NASDAQ:VANI) up 287% last week, insiders too were rewarded [Yahoo! Finance]
2/28
08:46 am
vani
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio [Yahoo! Finance]
High
Report
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio [Yahoo! Finance]
2/28
08:30 am
vani
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio
High
Report
Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio